DDInter1778 DDInter1676
A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Tetrabenazine {u} (Compound) resembles {v} (Compound) Donepezil
Tetrabenazine {u} (Compound) binds {v} (Gene) CYP2D6
Tetrabenazine {u} (Compound) upregulates {v} (Gene) WDR61
Tetrabenazine {u} (Compound) is included by {v} (Pharmacologic Class) Vesicular Monoamine Transporter 2 Inhibitors
Tetrabenazine {u} (Compound) downregulates {v} (Gene) GJA1
Tetrabenazine {u} (Compound) causes {v} (Side Effect) Insomnia
Tetrabenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Tetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Tetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Tetrabenazine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Tetrabenazine (Compound) resembles Donepezil (Compound)
Tetrabenazine (Compound) binds CYP2D6 (Gene)
Tetrabenazine (Compound) upregulates WDR61 (Gene)
Tetrabenazine (Compound) is included by Vesicular Monoamine Transporter 2 Inhibitors (Pharmacologic Class)
Tetrabenazine (Compound) downregulates GJA1 (Gene)
Tetrabenazine (Compound) causes Insomnia (Side Effect)
Tetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Tetrabenazine may lead to a major life threatening interaction when taken with Osimertinib